| 24.02 -0.4 (-1.64%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.17 | 1-year : | 32.01 |
| Resists | First : | 25.83 | Second : | 27.4 |
| Pivot price | 24.76  |
|||
| Supports | First : | 23.29 | Second : | 19.37 |
| MAs | MA(5) : | 23.99  |
MA(20) : | 24.85 |
| MA(100) : | 27.9 |
MA(250) : | 27.88 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 27.5 |
D(3) : | 23.2 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 35.56 | Low : | 23.29 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MIRM ] has closed above bottom band by 30.2%. Bollinger Bands are 0.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.94 - 25.07 | 25.07 - 25.17 |
| Low: | 23.56 - 23.69 | 23.69 - 23.79 |
| Close: | 23.81 - 24.03 | 24.03 - 24.2 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mon, 22 Apr 2024
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value (MIRM) - Seeking Alpha
Thu, 18 Apr 2024
Stifel starts Mirum at buy, cites IBATi drug potential (NASDAQ:MIRM) - Seeking Alpha
Tue, 02 Apr 2024
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by ... - Business Wire
Fri, 29 Mar 2024
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Wed, 13 Mar 2024
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with ... - Business Wire
Fri, 08 Mar 2024
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 112.1 (%) |
| Shares Short | 8,160 (K) |
| Shares Short P.Month | 7,660 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.32 |
| Profit Margin | -87.7 % |
| Operating Margin | -46.9 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -83.7 % |
| Qtrly Rev. Growth | 149.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.96 |
| EBITDA (p.s.) | -2.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -91 (M) |
| PE Ratio | -6.01 |
| PEG Ratio | 0 |
| Price to Book value | 4.51 |
| Price to Sales | 6.05 |
| Price to Cash Flow | -15.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|